Protalix BioTherapeutics, Inc. (PLX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenue | 15,658 | 17,959 | 13,474 | |
| Research and development expenses | 5,992 | 2,998 | 2,961 | |
| Cost of goods sold | 5,870 | 8,375 | 9,456 | |
| Selling, general and administrative expenses | 2,624 | 2,595 | 3,484 | |
| Operating income (loss) | 1,172 | 3,991 | -2,427 | |
| Other nonoperating expense | - | 299 | 367 | |
| Financial income | 272 | 151 | 522 | |
| Financial expenses | 783 | - | - | |
| Financial income (expenses), net | -511 | -148 | 155 | |
| Income (loss) before taxes on income | 661 | 3,843 | -2,272 | |
| Taxes on income (tax benefit) | 497 | 607 | -69 | |
| Net income (loss) | 164 | 3,236 | -2,203 | |
| Earnings per share, basic | - | 0.04 | -0.03 | |
| Earnings per share, diluted | - | 0.03 | -0.03 | |
| Weighted average number of shares outstanding, basic | 78,663,884 | 73,549,745 | 73,308,281 | |
| Weighted average number of shares outstanding, diluted | 81,271,610 | 81,217,068 | 73,308,281 | |